These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 19763434

  • 1. Epigenetics and ovarian cancer.
    Nephew KP, Balch C, Zhang S, Huang TH.
    Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
    [No Abstract] [Full Text] [Related]

  • 2. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S, Herceg Z.
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [Abstract] [Full Text] [Related]

  • 3. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP.
    Cancer Res; 2006 Jun 01; 66(11):5582-91. PubMed ID: 16740693
    [Abstract] [Full Text] [Related]

  • 4. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.
    Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A.
    J Cell Physiol; 2007 May 01; 211(2):287-95. PubMed ID: 17238139
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.
    J Cell Physiol; 2007 Aug 01; 212(2):330-44. PubMed ID: 17458893
    [Abstract] [Full Text] [Related]

  • 6. Epigenetic drugs take on cancer.
    Kaiser J.
    Science; 2010 Oct 29; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract] [Full Text] [Related]

  • 7. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
    Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, Yasugi T, Ushijima T.
    Cancer Lett; 2006 Sep 28; 241(2):213-20. PubMed ID: 16303245
    [Abstract] [Full Text] [Related]

  • 8. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.
    Expert Rev Anticancer Ther; 2007 Oct 28; 7(10):1439-49. PubMed ID: 17944568
    [Abstract] [Full Text] [Related]

  • 9. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF.
    Eur Urol; 2011 Oct 28; 60(4):753-66. PubMed ID: 21719191
    [Abstract] [Full Text] [Related]

  • 10. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
    Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, Korourian S, Baker VV, O'Brien TJ.
    J Soc Gynecol Investig; 1997 Oct 28; 4(2):95-102. PubMed ID: 9101469
    [Abstract] [Full Text] [Related]

  • 11. Epigenetics in ovarian cancer.
    Seeber LM, van Diest PJ.
    Methods Mol Biol; 2012 Oct 28; 863():253-69. PubMed ID: 22359298
    [Abstract] [Full Text] [Related]

  • 12. New players in ovarian cancer.
    Bovicelli A, D'Andrilli G, Giordano A.
    J Cell Physiol; 2011 Oct 28; 226(10):2500-4. PubMed ID: 21302305
    [Abstract] [Full Text] [Related]

  • 13. Epigenetic targeting in pancreatic cancer.
    van Kampen JG, Marijnissen-van Zanten MA, Simmer F, van der Graaf WT, Ligtenberg MJ, Nagtegaal ID.
    Cancer Treat Rev; 2014 Jun 28; 40(5):656-64. PubMed ID: 24433955
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R.
    Med Res Rev; 2005 May 28; 25(3):261-309. PubMed ID: 15717297
    [Abstract] [Full Text] [Related]

  • 15. [Epigenetics in hematological disorders].
    Furukawa Y.
    Rinsho Ketsueki; 2008 Oct 28; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract] [Full Text] [Related]

  • 16. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 17. Novel approaches on epigenetics.
    Papait R, Monti E, Bonapace IM.
    Curr Opin Drug Discov Devel; 2009 Mar 15; 12(2):264-75. PubMed ID: 19333872
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
    Bar-Sela G, Jacobs KM, Gius D.
    Cancer J; 2007 Mar 15; 13(1):65-9. PubMed ID: 17464248
    [Abstract] [Full Text] [Related]

  • 19. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
    De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, Gonzalez-Fierro A, Trejo-Becerril C, Chávez-Blanco A, Taja-Chayeb L, Vidal S, Gutiérrez O, Dominguez GI, Trujillo JE, Duenas-González A.
    Oncol Rep; 2011 Feb 15; 25(2):399-407. PubMed ID: 21152880
    [Abstract] [Full Text] [Related]

  • 20. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
    Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N, Dahiya R.
    Biochem Biophys Res Commun; 2004 Apr 16; 316(4):1156-62. PubMed ID: 15044106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.